In Russia there is a new drug for the treatment of CLL and MCL

News Project Concord
by

Company AstraZeneca announced that in Russia the registration certificate for calibrating intended for the treatment of chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/MLL) and relapsing/refractory (R/R) form multinacional lymphoma (MCL).

Calibrating is a new highly selective inhibitor of TKB second generation. This drug does not inhibit other tyrosine kinases, particularly EGF, ITK or TEC, so the clinical efficacy of the drug in trials was accompanied by the development of a smaller quantity unwanted effects such as bleeding and arrhythmias.

Approval of the drug in Russia was obtained on the basis of results of randomized clinical phase III studies (ELEVATE TN, CLL 1st line; ASCEND, R/R form of CLL; ACE-LY-004, R/R form ΜL).

In the reference study of the drug in first line therapy of CLL ELEVATE-TN, calibrating showed a statistically and clinically significant improvement in survival without progression (VBP) in patients receiving the drug in combination with aminotetralin or as monotherapy in comparison with standard therapy. The risk of disease progression or death in the combination therapy group with calibratiion decreased by 90% and in the group of monotherapy with calibration ― 80%. In the study, ASCEND (R/R CLL), the drug also showed high efficiency in comparison with the modes idealism with rituximab and bendamustine with rituximab: the estimated survival rate during the year without progression was 88% relative risk reduction of progression or death was 69%, the overall survival rate during the year was 94%.

Study of ACE-LY-004 was the registration for the readings of R/R MCL. The use of calibrating patients with the given pathology ensured a high frequency of long responses (frequency the overall response rate was 81%, and by the 12th month duration of response was 72%), estimated overall survival at one year was 87% with a median VBP not achieved.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

by

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]

by